Contact
Please use this form to send email to PR contact of this press release:
Armis Biopharma Granted QIDP for Lead Product, Ximycin(TM) for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery
TO: